prikaz prve stranice dokumenta Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report
  Download
PDF 4.3 MB
Scientific paper - Review paper
Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report
Journal of Drug Targeting, x (2024), x; 1-11. https://doi.org/10.1080/1061186X.2024.2332733
Tomić, Krešimir; Krpina, Kristina; Batičić, Lara; Samaržija, Miroslav; Vranić, Semir

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Tomić, K., Krpina, K., Batičić, L., Samaržija, M. & Vranić, S. (2024). Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report. Journal of Drug Targeting, x. (x), 1-11. doi: 10.1080/1061186X.2024.2332733

Tomić, Krešimir, et al. "Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report." Journal of Drug Targeting, vol. x, no. x, 2024, pp. 1-11. https://doi.org/10.1080/1061186X.2024.2332733

Tomić, Krešimir, Kristina Krpina, Lara Batičić, Miroslav Samaržija and Semir Vranić. "Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report." Journal of Drug Targeting x, no. x (2024): 1-11. https://doi.org/10.1080/1061186X.2024.2332733

Tomić, K., et al. (2024) 'Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report', Journal of Drug Targeting, x(x), pp. 1-11. doi: 10.1080/1061186X.2024.2332733

Tomić K, Krpina K, Batičić L, Samaržija M, Vranić S. Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report. Journal of Drug Targeting [Internet]. 2024 March 25 [cited 2024 November 05];x(x):1-11. doi: 10.1080/1061186X.2024.2332733

K. Tomić, K. Krpina, L. Batičić, M. Samaržija and S. Vranić, "Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report", Journal of Drug Targeting, vol. x, no. x, pp. 1-11, March 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:634605. [Accessed: 05 November 2024]

Metadata
Title (english)Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report
AuthorKrešimir Tomić
AuthorKristina Krpina
AuthorLara Batičić
AuthorMiroslav Samaržija
AuthorSemir Vranić
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Chemistry and Biochemistry)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Oncology
Abstract (english)
Histologic transformation to small cell lung cancer (tSCLC) is a rare but increasingly recognised mechanism of acquired resistance to tyrosine kinase inhibitors (TKI) in patients with epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). Beyond its acknowledged role in TKI resistance, histologic transformation to SCLC might be an important, yet under-recognised, mechanism of resistance in NSCLC treated with immunotherapy. Our review identified 32 studies that investigated tSCLC development in patients with EGFR-mutated NSCLC treated with TKI therapy and 16 case reports of patients treated with immunotherapy. It revealed the rarity of tSCLC, with a predominance of EGFR exon 19 mutations and limited therapeutic options and outcomes. Across all analysed studies in EGFR-mutated NSCLC treated with TKI therapy, the median time to tSCLC development was similar to 17 months, with a median overall survival of 10 months. Histologic transformation of EGFR-mutated NSCLC to SCLC is a rare, but challenging clinical problem with a poor prognosis. A small number of documented cases of tSCLC after immunotherapy highlight the need for rebiopsies at progression to diagnose this potential resistance mechanism. Further research is needed to better understand the mechanisms underlying this phenomenon and to develop more effective treatment strategies for patients with tSCLC.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleJournal of Drug Targeting
Numberingvol. x, no. x, pp. 1-11
p-ISSN1061-186X
e-ISSN1029-2330
DOIhttps://doi.org/10.1080/1061186X.2024.2332733
URN:NBNurn:nbn:hr:184:634605
Publication2024-03-25
Document URLhttps://www.tandfonline.com/doi/full/10.1080/1061186X.2024.2332733
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) icon
Created on2024-04-29 09:04:27